DESCRIPTION
Biopharmaceutical company located in Bizkaia, dedicated to researching, developing, producing and marketing biological drugs based on the human microbiome. With MBK-01 in phase III (lyophilised faecal microbiota capsules), Mikrobiomik aims to be the first company in the world to market the first biological drug in the EU based on intestinal microbiota in the indication of Clostridioides difficile recurrence in the innovative format of oral capsules, in a single dose of 4 capsules.
Keywords
Biotechnology, Microbiota, Clostridioides difficile.
